Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Divestments (2021)

Maravai Lifesciences Holdings has reported Divestments over the past 1 years, most recently at $120.7 million for Q3 2021.

  • Quarterly results put Divestments at $120.7 million for Q3 2021, changed N/A from a year ago — trailing twelve months through Dec 2023 was $120.7 million (changed N/A YoY), and the annual figure for FY2022 was $620000.0, down 99.48%.
  • Divestments for Q3 2021 was $120.7 million at Maravai Lifesciences Holdings.
  • Over the last five years, Divestments for MRVI hit a ceiling of $120.7 million in Q3 2021 and a floor of $120.7 million in Q3 2021.